Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTN3A1 | O00481 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | CCR6 | P51684 | 1/20 | 0.33 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CETP | P11597 | 3/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31480692 | 0.92 | BTN3A1 (0.36) | BTN3A1L3MBTL1CCR6PAX8TSHR | |
| SCHEMBL31480647 | 0.88 | BTN3A1 (0.37) | BTN3A1KMT2AALDH1A1L3MBTL1MAPK1 | |
| SCHEMBL31480854 | 0.84 | ALDH1A1 (0.37) | BTN3A1KMT2AALDH1A1L3MBTL1MAPK1 | |
| SCHEMBL31480801 | 0.82 | ALDH1A1 (0.44) | KMT2AALDH1A1L3MBTL1MAPK1CCR6 | |
| SCHEMBL31480709 | 0.82 | CCR6 (0.41) | KMT2AALDH1A1L3MBTL1MAPK1CCR6 | |
| SCHEMBL31480733 | 0.81 | ALDH1A1 (0.36) | KMT2AALDH1A1L3MBTL1MAPK1CCR6 | |
| SCHEMBL31480720 | 0.81 | ALDH1A1 (0.40) | ALDH1A1L3MBTL1MAPK1CCR6PAX8 | |
| SCHEMBL31447906 | 0.80 | CCR6 (0.48) | BTN3A1KMT2AALDH1A1L3MBTL1MAPK1 | |
| SCHEMBL31480820 | 0.80 | CCR6 (0.41) | KMT2AALDH1A1L3MBTL1MAPK1CCR6 | |
| SCHEMBL31480875 | 0.80 | BTN3A1 (0.36) | BTN3A1TSHRCETP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025080879-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2025-04-17 | — | — | WO | disclosed |
| US-20250120989-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2025-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250120989-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOF | SDHA, SDHB, DPYD | BTN3A1 4478/4885KMT2A 3060/4885ALDH1A1 684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.